If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Marco Palla is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Squamous Cell Neoplasms Medicine & Life Sciences
Skin Medicine & Life Sciences
Skin Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2018

  • 649 Citations
  • 11 h-Index
  • 20 Article
  • 1 Letter
  • 1 Review article
6 Citations (Scopus)

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer

Cavalieri, S., Ascierto, P. A., Locati, L. D., Bergamini, C., Granata, R., Galbiati, D., Ruggeri, R. & Palla, M., Jul 1 2018, In : European Journal of Cancer. 97, p. 7-15 9 p.

Research output: Contribution to journalArticle

Squamous Cell Neoplasms
Skin Neoplasms
Epidermal Growth Factor Receptor
Safety
Radiotherapy
Squamous Cell Neoplasms
Skin Neoplasms
Epidermal Growth Factor Receptor
Safety
Radiotherapy

Amelanotic metastatic melanoma of the stomach presenting with iron deficiency anemia

Iadevaia, M. D., Sgambato, D., Miranda, A., Ferrante, E., Federico, A., Sasso, F. C., D’Armiento, F. P., Palla, M. & Romano, M., 2017, In : Acta Gastro-Enterologica Belgica. 80, 2, p. 327-328 2 p.

Research output: Contribution to journalLetter

28 Citations (Scopus)

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

Simeone, E., Grimaldi, A. M., Festino, L., Vanella, V., Palla, M. & Ascierto, P. A., Feb 1 2017, In : BioDrugs. 31, 1, p. 51-61 11 p.

Research output: Contribution to journalReview article

Mitogen-Activated Protein Kinase Kinases
Standard of Care
Melanoma
Immunotherapy
Therapeutics
9 Citations (Scopus)

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Simeone, E., Grimaldi, A. M., Festino, L., Giannarelli, D., Vanella, V., Palla, M., Curvietto, M., Esposito, A., Palmieri, G., Mozzillo, N. & Ascierto, P. A., Mar 4 2017, In : OncoImmunology. 6, 3, e1283462.

Research output: Contribution to journalArticle

Melanoma
Immunotherapy
Therapeutics
Disease-Free Survival
pembrolizumab